<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD with MathML3 v1.1 20151215//EN" "JATS-journalpublishing1-mathml3.dtd">
<article dtd-version="1.1" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">
    <front>
        <journal-meta>
            <journal-id></journal-id>
            <issn></issn>
        </journal-meta>
        <article-meta>
            <title-group>
                <article-title></article-title>
            </title-group>
            <pub-date>
                <year></year>
            </pub-date>
        </article-meta> 
    </front>
    <back>
        <ref-list>
            <ref id="b1">
                <label>1. </label> 
                <mixed-citation publication-type="book">
                    <person-group><name><surname></surname></name></person-group>
                    <source>Rak v Sloveniji 2015</source>. 
                    <publisher-loc>Ljubljana</publisher-loc>:
                    <publisher-name>Onkološki inštitut Ljubljana, Epidemiologija in register raka, Register raka Republike Slovenije</publisher-name>;
                    <year>2016</year>.
                </mixed-citation>
            </ref>
            <ref id="b2">
                <label>2. </label> 
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name>
                            <surname>Zamorano</surname>
                            <given-names>JL</given-names>
                        </name>, 
                        <name>
                            <surname>Lancellotti</surname>
                            <given-names>P</given-names>
                        </name>, 
                        <name>
                            <surname>Rodriguez Muñoz</surname>
                            <given-names>D</given-names>
                        </name>, 
                        <name>
                            <surname>Aboyans</surname>
                            <given-names>V</given-names>
                        </name>, 
                        <name>
                            <surname>Asteggiano</surname>
                            <given-names>R</given-names>
                        </name>, 
                        <name>
                            <surname>Galderisi</surname>
                            <given-names>M</given-names>
                        </name>, 
                        <etal>et al</etal>; 
                        <collab>ESC Scientific Document Group</collab>
                    </person-group>. 
                    <article-title>2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: the Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC)</article-title>. 
                    <source>Eur Heart J</source>. 
                    <year>2016</year>
                    <month>Sep</month>;
                    <volume>37</volume>(
                    <issue>36</issue>):
                    <fpage>2768</fpage>–
                    <lpage>801</lpage>. 
                    <pub-id pub-id-type="doi">10.1093/eurheartj/ehw211</pub-id>
                    <pub-id pub-id-type="pmid">27567406</pub-id>
                    <issn>0195-668X</issn>
                </mixed-citation>
            </ref>
            <ref id="b3">
                <label>3. </label> 
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name>
                            <surname>Ewer</surname>
                            <given-names>MS</given-names>
                        </name>, 
                        <name>
                            <surname>Lippman</surname>
                            <given-names>SM</given-names>
                        </name>
                    </person-group>. 
                    <article-title>Type II chemotherapy-related cardiac dysfunction: time to recognize a new entity</article-title>. 
                    <source>J Clin Oncol</source>. 
                    <year>2005</year>
                    <month>May</month>;
                    <volume>23</volume>(
                    <issue>13</issue>):
                    <fpage>2900</fpage>–
                    <lpage>2</lpage>. 
                    <pub-id pub-id-type="doi">10.1200/JCO.2005.05.827</pub-id>
                    <pub-id pub-id-type="pmid">15860848</pub-id>
                    <issn>0732-183X</issn>
                </mixed-citation>
            </ref>
            <ref id="b4">
                <label>4. </label> 
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name>
                            <surname>Plana</surname>
                            <given-names>JC</given-names>
                        </name>, 
                        <name>
                            <surname>Galderisi</surname>
                            <given-names>M</given-names>
                        </name>, 
                        <name>
                            <surname>Barac</surname>
                            <given-names>A</given-names>
                        </name>, 
                        <name>
                            <surname>Ewer</surname>
                            <given-names>MS</given-names>
                        </name>, 
                        <name>
                            <surname>Ky</surname>
                            <given-names>B</given-names>
                        </name>, 
                        <name>
                            <surname>Scherrer-Crosbie</surname>
                            <given-names>M</given-names>
                        </name>, 
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging</article-title>. 
                    <source>J Am Soc Echocardiogr</source>. 
                    <year>2014</year>
                    <month>Sep</month>;
                    <volume>27</volume>(
                    <issue>9</issue>):
                    <fpage>911</fpage>–
                    <lpage>39</lpage>. 
                    <pub-id pub-id-type="doi">10.1016/j.echo.2014.07.012</pub-id>
                    <pub-id pub-id-type="pmid">25172399</pub-id>
                    <issn>0894-7317</issn>
                </mixed-citation>
            </ref>
            <ref id="b5">
                <label>5. </label> 
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name>
                            <surname>Bloom</surname>
                            <given-names>MW</given-names>
                        </name>, 
                        <name>
                            <surname>Hamo</surname>
                            <given-names>CE</given-names>
                        </name>, 
                        <name>
                            <surname>Cardinale</surname>
                            <given-names>D</given-names>
                        </name>, 
                        <name>
                            <surname>Ky</surname>
                            <given-names>B</given-names>
                        </name>, 
                        <name>
                            <surname>Nohria</surname>
                            <given-names>A</given-names>
                        </name>, 
                        <name>
                            <surname>Baer</surname>
                            <given-names>L</given-names>
                        </name>, 
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>Cancer Therapy-Related Cardiac Dysfunction and Heart Failure: Part 1: Definitions, Pathophysiology, Risk Factors, and Imaging</article-title>. 
                    <source>Circ Heart Fail</source>. 
                    <year>2016</year>
                    <month>Jan</month>;
                    <volume>9</volume>(
                    <issue>1</issue>):
                    <fpage>e002661</fpage>. 
                    <pub-id pub-id-type="doi">10.1161/CIRCHEARTFAILURE.115.002661</pub-id>
                    <pub-id pub-id-type="pmid">26747861</pub-id>
                    <issn>1941-3289</issn>
                </mixed-citation>
            </ref>
            <ref id="b6">
                <label>6. </label> 
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name>
                            <surname>Curigliano</surname>
                            <given-names>G</given-names>
                        </name>, 
                        <name>
                            <surname>Lenihan</surname>
                            <given-names>D</given-names>
                        </name>, 
                        <name>
                            <surname>Fradley</surname>
                            <given-names>M</given-names>
                        </name>, 
                        <name>
                            <surname>Ganatra</surname>
                            <given-names>S</given-names>
                        </name>, 
                        <name>
                            <surname>Barac</surname>
                            <given-names>A</given-names>
                        </name>, 
                        <name>
                            <surname>Blaes</surname>
                            <given-names>A</given-names>
                        </name>, 
                        <etal>et al</etal>; 
                        <collab>ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org</collab>
                    </person-group>. 
                    <article-title>Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations</article-title>. 
                    <source>Ann Oncol</source>. 
                    <year>2020</year>
                    <month>Feb</month>;
                    <volume>31</volume>(
                    <issue>2</issue>):
                    <fpage>171</fpage>–
                    <lpage>90</lpage>. 
                    <pub-id pub-id-type="doi">10.1016/j.annonc.2019.10.023</pub-id>
                    <pub-id pub-id-type="pmid">31959335</pub-id>
                    <issn>0923-7534</issn>
                </mixed-citation>
            </ref>
            <ref id="b7">
                <label>7. </label> 
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name>
                            <surname>Lyu</surname>
                            <given-names>YL</given-names>
                        </name>, 
                        <name>
                            <surname>Kerrigan</surname>
                            <given-names>JE</given-names>
                        </name>, 
                        <name>
                            <surname>Lin</surname>
                            <given-names>CP</given-names>
                        </name>, 
                        <name>
                            <surname>Azarova</surname>
                            <given-names>AM</given-names>
                        </name>, 
                        <name>
                            <surname>Tsai</surname>
                            <given-names>YC</given-names>
                        </name>, 
                        <name>
                            <surname>Ban</surname>
                            <given-names>Y</given-names>
                        </name>, 
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>Topoisomerase IIbeta mediated DNA double-strand breaks: implications in doxorubicin cardiotoxicity and prevention by dexrazoxane</article-title>. 
                    <source>Cancer Res</source>. 
                    <year>2007</year>
                    <month>Sep</month>;
                    <volume>67</volume>(
                    <issue>18</issue>):
                    <fpage>8839</fpage>–
                    <lpage>46</lpage>. 
                    <pub-id pub-id-type="doi">10.1158/0008-5472.CAN-07-1649</pub-id>
                    <pub-id pub-id-type="pmid">17875725</pub-id>
                    <issn>0008-5472</issn>
                </mixed-citation>
            </ref>
            <ref id="b8">
                <label>8. </label> 
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name>
                            <surname>Blanco</surname>
                            <given-names>JG</given-names>
                        </name>, 
                        <name>
                            <surname>Sun</surname>
                            <given-names>CL</given-names>
                        </name>, 
                        <name>
                            <surname>Landier</surname>
                            <given-names>W</given-names>
                        </name>, 
                        <name>
                            <surname>Chen</surname>
                            <given-names>L</given-names>
                        </name>, 
                        <name>
                            <surname>Esparza-Duran</surname>
                            <given-names>D</given-names>
                        </name>, 
                        <name>
                            <surname>Leisenring</surname>
                            <given-names>W</given-names>
                        </name>, 
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>Anthracycline-related cardiomyopathy after childhood cancer: role of polymorphisms in carbonyl reductase genes—a report from the Children’s Oncology Group</article-title>. 
                    <source>J Clin Oncol</source>. 
                    <year>2012</year>
                    <month>May</month>;
                    <volume>30</volume>(
                    <issue>13</issue>):
                    <fpage>1415</fpage>–
                    <lpage>21</lpage>. 
                    <pub-id pub-id-type="doi">10.1200/JCO.2011.34.8987</pub-id>
                    <pub-id pub-id-type="pmid">22124095</pub-id>
                    <issn>0732-183X</issn>
                </mixed-citation>
            </ref>
            <ref id="b9">
                <label>9. </label> 
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name>
                            <surname>Cardinale</surname>
                            <given-names>D</given-names>
                        </name>, 
                        <name>
                            <surname>Colombo</surname>
                            <given-names>A</given-names>
                        </name>, 
                        <name>
                            <surname>Bacchiani</surname>
                            <given-names>G</given-names>
                        </name>, 
                        <name>
                            <surname>Tedeschi</surname>
                            <given-names>I</given-names>
                        </name>, 
                        <name>
                            <surname>Meroni</surname>
                            <given-names>CA</given-names>
                        </name>, 
                        <name>
                            <surname>Veglia</surname>
                            <given-names>F</given-names>
                        </name>, 
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy</article-title>. 
                    <source>Circulation</source>. 
                    <year>2015</year>
                    <month>Jun</month>;
                    <volume>131</volume>(
                    <issue>22</issue>):
                    <fpage>1981</fpage>–
                    <lpage>8</lpage>. 
                    <pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.114.013777</pub-id>
                    <pub-id pub-id-type="pmid">25948538</pub-id>
                    <issn>0009-7322</issn>
                </mixed-citation>
            </ref>
            <ref id="b10">
                <label>10. </label> 
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name>
                            <surname>Steinherz</surname>
                            <given-names>LJ</given-names>
                        </name>, 
                        <name>
                            <surname>Steinherz</surname>
                            <given-names>PG</given-names>
                        </name>, 
                        <name>
                            <surname>Tan</surname>
                            <given-names>CT</given-names>
                        </name>, 
                        <name>
                            <surname>Heller</surname>
                            <given-names>G</given-names>
                        </name>, 
                        <name>
                            <surname>Murphy</surname>
                            <given-names>ML</given-names>
                        </name>
                    </person-group>. 
                    <article-title>Cardiac toxicity 4 to 20 years after completing anthracycline therapy</article-title>. 
                    <source>JAMA</source>. 
                    <year>1991</year>
                    <month>Sep</month>;
                    <volume>266</volume>(
                    <issue>12</issue>):
                    <fpage>1672</fpage>–
                    <lpage>7</lpage>. 
                    <pub-id pub-id-type="doi">10.1001/jama.1991.03470120074036</pub-id>
                    <pub-id pub-id-type="pmid">1886191</pub-id>
                    <issn>0098-7484</issn>
                </mixed-citation>
            </ref>
            <ref id="b11">
                <label>11. </label> 
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name>
                            <surname>Cardinale</surname>
                            <given-names>D</given-names>
                        </name>, 
                        <name>
                            <surname>Colombo</surname>
                            <given-names>A</given-names>
                        </name>, 
                        <name>
                            <surname>Lamantia</surname>
                            <given-names>G</given-names>
                        </name>, 
                        <name>
                            <surname>Colombo</surname>
                            <given-names>N</given-names>
                        </name>, 
                        <name>
                            <surname>Civelli</surname>
                            <given-names>M</given-names>
                        </name>, 
                        <name>
                            <surname>De Giacomi</surname>
                            <given-names>G</given-names>
                        </name>, 
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy</article-title>. 
                    <source>J Am Coll Cardiol</source>. 
                    <year>2010</year>
                    <month>Jan</month>;
                    <volume>55</volume>(
                    <issue>3</issue>):
                    <fpage>213</fpage>–
                    <lpage>20</lpage>. 
                    <pub-id pub-id-type="doi">10.1016/j.jacc.2009.03.095</pub-id>
                    <pub-id pub-id-type="pmid">20117401</pub-id>
                    <issn>0735-1097</issn>
                </mixed-citation>
            </ref>
            <ref id="b12">
                <label>12. </label> 
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name>
                            <surname>Bowles</surname>
                            <given-names>EJ</given-names>
                        </name>, 
                        <name>
                            <surname>Wellman</surname>
                            <given-names>R</given-names>
                        </name>, 
                        <name>
                            <surname>Feigelson</surname>
                            <given-names>HS</given-names>
                        </name>, 
                        <name>
                            <surname>Onitilo</surname>
                            <given-names>AA</given-names>
                        </name>, 
                        <name>
                            <surname>Freedman</surname>
                            <given-names>AN</given-names>
                        </name>, 
                        <name>
                            <surname>Delate</surname>
                            <given-names>T</given-names>
                        </name>, 
                        <etal>et al</etal>; 
                        <collab>Pharmacovigilance Study Team</collab>
                    </person-group>. 
                    <article-title>Risk of heart failure in breast cancer patients after anthracycline and trastuzumab treatment: a retrospective cohort study</article-title>. 
                    <source>J Natl Cancer Inst</source>. 
                    <year>2012</year>
                    <month>Sep</month>;
                    <volume>104</volume>(
                    <issue>17</issue>):
                    <fpage>1293</fpage>–
                    <lpage>305</lpage>. 
                    <pub-id pub-id-type="doi">10.1093/jnci/djs317</pub-id>
                    <pub-id pub-id-type="pmid">22949432</pub-id>
                    <issn>0027-8874</issn>
                </mixed-citation>
            </ref>
            <ref id="b13">
                <label>13. </label> 
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name>
                            <surname>Moja</surname>
                            <given-names>L</given-names>
                        </name>, 
                        <name>
                            <surname>Tagliabue</surname>
                            <given-names>L</given-names>
                        </name>, 
                        <name>
                            <surname>Balduzzi</surname>
                            <given-names>S</given-names>
                        </name>, 
                        <name>
                            <surname>Parmelli</surname>
                            <given-names>E</given-names>
                        </name>, 
                        <name>
                            <surname>Pistotti</surname>
                            <given-names>V</given-names>
                        </name>, 
                        <name>
                            <surname>Guarneri</surname>
                            <given-names>V</given-names>
                        </name>, 
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>Trastuzumab containing regimens for early breast cancer</article-title>. 
                    <source>Cochrane Database Syst Rev</source>. 
                    <year>2012</year>
                    <month>Apr</month>;
                    <volume>4</volume>(
                    <issue>4</issue>):
                    <fpage>CD006243</fpage>. 
                    <pub-id pub-id-type="doi">10.1002/14651858.CD006243.pub2</pub-id>
                    <pub-id pub-id-type="pmid">22513938</pub-id>
                    <issn>1469-493X</issn>
                </mixed-citation>
            </ref>
            <ref id="b14">
                <label>14. </label>
                <mixed-citation publication-type="book">
                    <person-group person-group-type="author">
                        <name>
                            <surname>Žgajnar</surname>
                            <given-names>J.</given-names>
                        </name>
                    </person-group>
                    <source>Smernice diagnostike in zdravljenja raka dojk</source>.
                    <publisher-loc>Ljubljana</publisher-loc>:
                    <publisher-name>Onkološki inštitut Ljubljana</publisher-name>;
                    <year>2014</year>.
                </mixed-citation>
            </ref>
            <ref id="b15">
                <label>15. </label> 
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name>
                            <surname>Lenihan</surname>
                            <given-names>D</given-names>
                        </name>, 
                        <name>
                            <surname>Suter</surname>
                            <given-names>T</given-names>
                        </name>, 
                        <name>
                            <surname>Brammer</surname>
                            <given-names>M</given-names>
                        </name>, 
                        <name>
                            <surname>Neate</surname>
                            <given-names>C</given-names>
                        </name>, 
                        <name>
                            <surname>Ross</surname>
                            <given-names>G</given-names>
                        </name>, 
                        <name>
                            <surname>Baselga</surname>
                            <given-names>J</given-names>
                        </name>
                    </person-group>. 
                    <article-title>Pooled analysis of cardiac safety in patients with cancer treated with pertuzumab</article-title>. 
                    <source>Ann Oncol</source>. 
                    <year>2012</year>
                    <month>Mar</month>;
                    <volume>23</volume>(
                    <issue>3</issue>):
                    <fpage>791</fpage>–
                    <lpage>800</lpage>. 
                    <pub-id pub-id-type="doi">10.1093/annonc/mdr294</pub-id>
                    <pub-id pub-id-type="pmid">21665955</pub-id>
                    <issn>0923-7534</issn>
                </mixed-citation>
            </ref>
            <ref id="b16">
                <label>16. </label> 
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name>
                            <surname>Krop</surname>
                            <given-names>IE</given-names>
                        </name>, 
                        <name>
                            <surname>Suter</surname>
                            <given-names>TM</given-names>
                        </name>, 
                        <name>
                            <surname>Dang</surname>
                            <given-names>CT</given-names>
                        </name>, 
                        <name>
                            <surname>Dirix</surname>
                            <given-names>L</given-names>
                        </name>, 
                        <name>
                            <surname>Romieu</surname>
                            <given-names>G</given-names>
                        </name>, 
                        <name>
                            <surname>Zamagni</surname>
                            <given-names>C</given-names>
                        </name>, 
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>Feasibility and cardiac safety of trastuzumab emtansine after anthracycline-based chemotherapy as (neo)adjuvant therapy for human epidermal growth factor receptor 2-positive early-stage breast cancer</article-title>. 
                    <source>J Clin Oncol</source>. 
                    <year>2015</year>
                    <month>Apr</month>;
                    <volume>33</volume>(
                    <issue>10</issue>):
                    <fpage>1136</fpage>–
                    <lpage>42</lpage>. 
                    <pub-id pub-id-type="doi">10.1200/JCO.2014.58.7782</pub-id>
                    <pub-id pub-id-type="pmid">25713436</pub-id>
                    <issn>0732-183X</issn>
                </mixed-citation>
            </ref>
            <ref id="b17">
                <label>17. </label> 
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name>
                            <surname>Piccart-Gebhart</surname>
                            <given-names>M</given-names>
                        </name>, 
                        <name>
                            <surname>Holmes</surname>
                            <given-names>E</given-names>
                        </name>, 
                        <name>
                            <surname>Baselga</surname>
                            <given-names>J</given-names>
                        </name>, 
                        <name>
                            <surname>de Azambuja</surname>
                            <given-names>E</given-names>
                        </name>, 
                        <name>
                            <surname>Dueck</surname>
                            <given-names>AC</given-names>
                        </name>, 
                        <name>
                            <surname>Viale</surname>
                            <given-names>G</given-names>
                        </name>, 
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>Adjuvant lapatinib and trastuzumab for early human epidermal growth factor receptor 2-positive breast cancer: results from the randomized phase III Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization trial</article-title>. 
                    <source>J Clin Oncol</source>. 
                    <year>2016</year>
                    <month>Apr</month>;
                    <volume>34</volume>(
                    <issue>10</issue>):
                    <fpage>1034</fpage>–
                    <lpage>42</lpage>. 
                    <pub-id pub-id-type="doi">10.1200/JCO.2015.62.1797</pub-id>
                    <pub-id pub-id-type="pmid">26598744</pub-id>
                    <issn>0732-183X</issn>
                </mixed-citation>
            </ref>
            <ref id="b18">
                <label>18. </label> 
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name>
                            <surname>Ghatalia</surname>
                            <given-names>P</given-names>
                        </name>, 
                        <name>
                            <surname>Morgan</surname>
                            <given-names>CJ</given-names>
                        </name>, 
                        <name>
                            <surname>Je</surname>
                            <given-names>Y</given-names>
                        </name>, 
                        <name>
                            <surname>Nguyen</surname>
                            <given-names>PL</given-names>
                        </name>, 
                        <name>
                            <surname>Trinh</surname>
                            <given-names>QD</given-names>
                        </name>, 
                        <name>
                            <surname>Choueiri</surname>
                            <given-names>TK</given-names>
                        </name>, 
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>Congestive heart failure with vascular endothelial growth factor receptor tyrosine kinase inhibitors</article-title>. 
                    <source>Crit Rev Oncol Hematol</source>. 
                    <year>2015</year>
                    <month>May</month>;
                    <volume>94</volume>(
                    <issue>2</issue>):
                    <fpage>228</fpage>–
                    <lpage>37</lpage>. 
                    <pub-id pub-id-type="doi">10.1016/j.critrevonc.2014.12.008</pub-id>
                    <pub-id pub-id-type="pmid">25577572</pub-id>
                    <issn>1040-8428</issn>
                </mixed-citation>
            </ref>
            <ref id="b19">
                <label>19. </label> 
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name>
                            <surname>Jaworski</surname>
                            <given-names>C</given-names>
                        </name>, 
                        <name>
                            <surname>Mariani</surname>
                            <given-names>JA</given-names>
                        </name>, 
                        <name>
                            <surname>Wheeler</surname>
                            <given-names>G</given-names>
                        </name>, 
                        <name>
                            <surname>Kaye</surname>
                            <given-names>DM</given-names>
                        </name>
                    </person-group>. 
                    <article-title>Cardiac complications of thoracic irradiation</article-title>. 
                    <source>J Am Coll Cardiol</source>. 
                    <year>2013</year>
                    <month>Jun</month>;
                    <volume>61</volume>(
                    <issue>23</issue>):
                    <fpage>2319</fpage>–
                    <lpage>28</lpage>. 
                    <pub-id pub-id-type="doi">10.1016/j.jacc.2013.01.090</pub-id>
                    <pub-id pub-id-type="pmid">23583253</pub-id>
                    <issn>0735-1097</issn>
                </mixed-citation>
            </ref>
            <ref id="b20">
                <label>20. </label> 
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name>
                            <surname>Filopei</surname>
                            <given-names>J</given-names>
                        </name>, 
                        <name>
                            <surname>Frishman</surname>
                            <given-names>W</given-names>
                        </name>
                    </person-group>. 
                    <article-title>Radiation-induced heart disease</article-title>. 
                    <source>Cardiol Rev</source>. 
                    <year>2012</year>
                    <month>Jul-Aug</month>;
                    <volume>20</volume>(
                    <issue>4</issue>):
                    <fpage>184</fpage>–
                    <lpage>8</lpage>. 
                    <pub-id pub-id-type="doi">10.1097/CRD.0b013e3182431c23</pub-id>
                    <pub-id pub-id-type="pmid">22314140</pub-id>
                    <issn>1061-5377</issn>
                </mixed-citation>
            </ref>
            <ref id="b21">
                <label>21. </label> 
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name>
                            <surname>van Nimwegen</surname>
                            <given-names>FA</given-names>
                        </name>, 
                        <name>
                            <surname>Schaapveld</surname>
                            <given-names>M</given-names>
                        </name>, 
                        <name>
                            <surname>Janus</surname>
                            <given-names>CP</given-names>
                        </name>, 
                        <name>
                            <surname>Krol</surname>
                            <given-names>AD</given-names>
                        </name>, 
                        <name>
                            <surname>Petersen</surname>
                            <given-names>EJ</given-names>
                        </name>, 
                        <name>
                            <surname>Raemaekers</surname>
                            <given-names>JM</given-names>
                        </name>, 
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>Cardiovascular disease after Hodgkin lymphoma treatment: 40-year disease risk</article-title>. 
                    <source>JAMA Intern Med</source>. 
                    <year>2015</year>
                    <month>Jun</month>;
                    <volume>175</volume>(
                    <issue>6</issue>):
                    <fpage>1007</fpage>–
                    <lpage>17</lpage>. 
                    <pub-id pub-id-type="doi">10.1001/jamainternmed.2015.1180</pub-id>
                    <pub-id pub-id-type="pmid">25915855</pub-id>
                    <issn>2168-6106</issn>
                </mixed-citation>
            </ref>
            <ref id="b22">
                <label>22. </label> 
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name>
                            <surname>Matthews</surname>
                            <given-names>A</given-names>
                        </name>, 
                        <name>
                            <surname>Stanway</surname>
                            <given-names>S</given-names>
                        </name>, 
                        <name>
                            <surname>Farmer</surname>
                            <given-names>RE</given-names>
                        </name>, 
                        <name>
                            <surname>Strongman</surname>
                            <given-names>H</given-names>
                        </name>, 
                        <name>
                            <surname>Thomas</surname>
                            <given-names>S</given-names>
                        </name>, 
                        <name>
                            <surname>Lyon</surname>
                            <given-names>AR</given-names>
                        </name>, 
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>Long term adjuvant endocrine therapy and risk of cardiovascular disease in female breast cancer survivors: systematic review</article-title>. 
                    <source>BMJ</source>. 
                    <year>2018</year>
                    <month>Oct</month>;
                    <volume>363</volume>:
                    <fpage>k3845</fpage>. 
                    <pub-id pub-id-type="doi">10.1136/bmj.k3845</pub-id>
                    <pub-id pub-id-type="pmid">30297439</pub-id>
                    <issn>0959-8138</issn>
                </mixed-citation>
            </ref>
            <ref id="b23">
                <label>23. </label> 
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name>
                            <surname>Haanen</surname>
                            <given-names>J</given-names>
                        </name>, 
                        <name>
                            <surname>Carbonnel</surname>
                            <given-names>F</given-names>
                        </name>, 
                        <name>
                            <surname>Robert</surname>
                            <given-names>C</given-names>
                        </name>, 
                        <name>
                            <surname>Kerr</surname>
                            <given-names>K</given-names>
                        </name>, 
                        <name>
                            <surname>Peters</surname>
                            <given-names>S</given-names>
                        </name>, 
                        <name>
                            <surname>Larkin</surname>
                            <given-names>J</given-names>
                        </name>, 
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>Management of Toxicities from Immunotherapy: ESMO Clinical Practice Guidelines</article-title>. 
                    <source>Ann Oncol</source>. 
                    <year>2017</year>;
                    <volume>28</volume>(
                    <issue>4</issue>):
                    <fpage>iv119</fpage>–
                    <lpage>42</lpage>. 
                    <pub-id pub-id-type="doi">10.1093/annonc/mdx225</pub-id>
                    <issn>0923-7534</issn>
                </mixed-citation>
            </ref>
            <ref id="b24">
                <label>24. </label> 
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name>
                            <surname>Johnson</surname>
                            <given-names>DB</given-names>
                        </name>, 
                        <name>
                            <surname>Balko</surname>
                            <given-names>JM</given-names>
                        </name>, 
                        <name>
                            <surname>Compton</surname>
                            <given-names>ML</given-names>
                        </name>, 
                        <name>
                            <surname>Chalkias</surname>
                            <given-names>S</given-names>
                        </name>, 
                        <name>
                            <surname>Gorham</surname>
                            <given-names>J</given-names>
                        </name>, 
                        <name>
                            <surname>Xu</surname>
                            <given-names>Y</given-names>
                        </name>, 
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>Fulminant myocarditis with combination immune checkpoint blockade</article-title>. 
                    <source>N Engl J Med</source>. 
                    <year>2016</year>
                    <month>Nov</month>;
                    <volume>375</volume>(
                    <issue>18</issue>):
                    <fpage>1749</fpage>–
                    <lpage>55</lpage>. 
                    <pub-id pub-id-type="doi">10.1056/NEJMoa1609214</pub-id>
                    <pub-id pub-id-type="pmid">27806233</pub-id>
                    <issn>0028-4793</issn>
                </mixed-citation>
            </ref>
            <ref id="b25">
                <label>25. </label> 
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name>
                            <surname>Tadokoro</surname>
                            <given-names>T</given-names>
                        </name>, 
                        <name>
                            <surname>Keshino</surname>
                            <given-names>E</given-names>
                        </name>, 
                        <name>
                            <surname>Makiyama</surname>
                            <given-names>A</given-names>
                        </name>, 
                        <name>
                            <surname>Sasaguri</surname>
                            <given-names>T</given-names>
                        </name>, 
                        <name>
                            <surname>Ohshima</surname>
                            <given-names>K</given-names>
                        </name>, 
                        <name>
                            <surname>Katano</surname>
                            <given-names>H</given-names>
                        </name>, 
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>Acute lymphocytic myocarditis with anti-PD-1 antibody nivolumab</article-title>. 
                    <source>Circ Heart Fail</source>. 
                    <year>2016</year>
                    <month>Oct</month>;
                    <volume>9</volume>(
                    <issue>10</issue>):
                    <fpage>e003514</fpage>. 
                    <pub-id pub-id-type="doi">10.1161/CIRCHEARTFAILURE.116.003514</pub-id>
                    <pub-id pub-id-type="pmid">27650418</pub-id>
                    <issn>1941-3289</issn>
                </mixed-citation>
            </ref>
            <ref id="b26">
                <label>26. </label> 
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name>
                            <surname>Läubli</surname>
                            <given-names>H</given-names>
                        </name>, 
                        <name>
                            <surname>Balmelli</surname>
                            <given-names>C</given-names>
                        </name>, 
                        <name>
                            <surname>Bossard</surname>
                            <given-names>M</given-names>
                        </name>, 
                        <name>
                            <surname>Pfister</surname>
                            <given-names>O</given-names>
                        </name>, 
                        <name>
                            <surname>Glatz</surname>
                            <given-names>K</given-names>
                        </name>, 
                        <name>
                            <surname>Zippelius</surname>
                            <given-names>A</given-names>
                        </name>
                    </person-group>. 
                    <article-title>Acute heart failure due to autoimmune myocarditis under pembrolizumab treatment for metastatic melanoma</article-title>. 
                    <source>J Immunother Cancer</source>. 
                    <year>2015</year>
                    <month>Apr</month>;
                    <volume>3</volume>(
                    <issue>1</issue>):
                    <fpage>11</fpage>. 
                    <pub-id pub-id-type="doi">10.1186/s40425-015-0057-1</pub-id>
                    <pub-id pub-id-type="pmid">25901283</pub-id>
                    <issn>2051-1426</issn>
                </mixed-citation>
            </ref>
            <ref id="b27">
                <label>27. </label> 
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name>
                            <surname>Negishi</surname>
                            <given-names>K</given-names>
                        </name>, 
                        <name>
                            <surname>Negishi</surname>
                            <given-names>T</given-names>
                        </name>, 
                        <name>
                            <surname>Hare</surname>
                            <given-names>JL</given-names>
                        </name>, 
                        <name>
                            <surname>Haluska</surname>
                            <given-names>BA</given-names>
                        </name>, 
                        <name>
                            <surname>Plana</surname>
                            <given-names>JC</given-names>
                        </name>, 
                        <name>
                            <surname>Marwick</surname>
                            <given-names>TH</given-names>
                        </name>
                    </person-group>. 
                    <article-title>Independent and incremental value of deformation indices for prediction of trastuzumab-induced cardiotoxicity</article-title>. 
                    <source>J Am Soc Echocardiogr</source>. 
                    <year>2013</year>
                    <month>May</month>;
                    <volume>26</volume>(
                    <issue>5</issue>):
                    <fpage>493</fpage>–
                    <lpage>8</lpage>. 
                    <pub-id pub-id-type="doi">10.1016/j.echo.2013.02.008</pub-id>
                    <pub-id pub-id-type="pmid">23562088</pub-id>
                    <issn>0894-7317</issn>
                </mixed-citation>
            </ref>
            <ref id="b28">
                <label>28. </label> 
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name>
                            <surname>Thavendiranathan</surname>
                            <given-names>P</given-names>
                        </name>, 
                        <name>
                            <surname>Wintersperger</surname>
                            <given-names>BJ</given-names>
                        </name>, 
                        <name>
                            <surname>Flamm</surname>
                            <given-names>SD</given-names>
                        </name>, 
                        <name>
                            <surname>Marwick</surname>
                            <given-names>TH</given-names>
                        </name>
                    </person-group>. 
                    <article-title>Cardiac MRI in the assessment of cardiac injury and toxicity from cancer chemotherapy: a systematic review</article-title>. 
                    <source>Circ Cardiovasc Imaging</source>. 
                    <year>2013</year>
                    <month>Nov</month>;
                    <volume>6</volume>(
                    <issue>6</issue>):
                    <fpage>1080</fpage>–
                    <lpage>91</lpage>. 
                    <pub-id pub-id-type="doi">10.1161/CIRCIMAGING.113.000899</pub-id>
                    <pub-id pub-id-type="pmid">24254478</pub-id>
                    <issn>1941-9651</issn>
                </mixed-citation>
            </ref>
            <ref id="b29">
                <label>29. </label> 
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name>
                            <surname>Curigliano</surname>
                            <given-names>G</given-names>
                        </name>, 
                        <name>
                            <surname>Cardinale</surname>
                            <given-names>D</given-names>
                        </name>, 
                        <name>
                            <surname>Suter</surname>
                            <given-names>T</given-names>
                        </name>, 
                        <name>
                            <surname>Plataniotis</surname>
                            <given-names>G</given-names>
                        </name>, 
                        <name>
                            <surname>de Azambuja</surname>
                            <given-names>E</given-names>
                        </name>, 
                        <name>
                            <surname>Sandri</surname>
                            <given-names>MT</given-names>
                        </name>, 
                        <etal>et al</etal>; 
                        <collab>ESMO Guidelines Working Group</collab>
                    </person-group>. 
                    <article-title>Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice Guidelines</article-title>. 
                    <source>Ann Oncol</source>. 
                    <year>2012</year>
                    <month>Oct</month>;
                    <volume>23</volume>(
                    <issue>7</issue>
                    <supplement>Suppl 7</supplement>):
                    <fpage>vii155</fpage>–
                    <lpage>66</lpage>. 
                    <pub-id pub-id-type="doi">10.1093/annonc/mds293</pub-id>
                    <pub-id pub-id-type="pmid">22997448</pub-id>
                    <issn>0923-7534</issn>
                </mixed-citation>
            </ref>
            <ref id="b30">
                <label>30. </label> 
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name>
                            <surname>Hamo</surname>
                            <given-names>CE</given-names>
                        </name>, 
                        <name>
                            <surname>Bloom</surname>
                            <given-names>MW</given-names>
                        </name>, 
                        <name>
                            <surname>Cardinale</surname>
                            <given-names>D</given-names>
                        </name>, 
                        <name>
                            <surname>Ky</surname>
                            <given-names>B</given-names>
                        </name>, 
                        <name>
                            <surname>Nohria</surname>
                            <given-names>A</given-names>
                        </name>, 
                        <name>
                            <surname>Baer</surname>
                            <given-names>L</given-names>
                        </name>, 
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>Cancer Therapy-Related Cardiac Dysfunction and Heart Failure: Part 2: Prevention, Treatment, Guidelines, and Future Directions</article-title>. 
                    <source>Circ Heart Fail</source>. 
                    <year>2016</year>
                    <month>Feb</month>;
                    <volume>9</volume>(
                    <issue>2</issue>):
                    <fpage>e002843</fpage>. 
                    <pub-id pub-id-type="doi">10.1161/CIRCHEARTFAILURE.115.002843</pub-id>
                    <pub-id pub-id-type="pmid">26839395</pub-id>
                    <issn>1941-3289</issn>
                </mixed-citation>
            </ref>
            <ref id="b31">
                <label>31. </label> 
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name>
                            <surname>Cardinale</surname>
                            <given-names>D</given-names>
                        </name>, 
                        <name>
                            <surname>Bacchiani</surname>
                            <given-names>G</given-names>
                        </name>, 
                        <name>
                            <surname>Beggiato</surname>
                            <given-names>M</given-names>
                        </name>, 
                        <name>
                            <surname>Colombo</surname>
                            <given-names>A</given-names>
                        </name>, 
                        <name>
                            <surname>Cipolla</surname>
                            <given-names>CM</given-names>
                        </name>
                    </person-group>. 
                    <article-title>Strategies to prevent and treat cardiovascular risk in cancer patients</article-title>. 
                    <source>Semin Oncol</source>. 
                    <year>2013</year>
                    <month>Apr</month>;
                    <volume>40</volume>(
                    <issue>2</issue>):
                    <fpage>186</fpage>–
                    <lpage>98</lpage>. 
                    <pub-id pub-id-type="doi">10.1053/j.seminoncol.2013.01.008</pub-id>
                    <pub-id pub-id-type="pmid">23540744</pub-id>
                    <issn>0093-7754</issn>
                </mixed-citation>
            </ref>
            <ref id="b32">
                <label>32. </label> 
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name>
                            <surname>Cardinale</surname>
                            <given-names>D</given-names>
                        </name>, 
                        <name>
                            <surname>Sandri</surname>
                            <given-names>MT</given-names>
                        </name>, 
                        <name>
                            <surname>Colombo</surname>
                            <given-names>A</given-names>
                        </name>, 
                        <name>
                            <surname>Colombo</surname>
                            <given-names>N</given-names>
                        </name>, 
                        <name>
                            <surname>Boeri</surname>
                            <given-names>M</given-names>
                        </name>, 
                        <name>
                            <surname>Lamantia</surname>
                            <given-names>G</given-names>
                        </name>, 
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy</article-title>. 
                    <source>Circulation</source>. 
                    <year>2004</year>
                    <month>Jun</month>;
                    <volume>109</volume>(
                    <issue>22</issue>):
                    <fpage>2749</fpage>–
                    <lpage>54</lpage>. 
                    <pub-id pub-id-type="doi">10.1161/01.CIR.0000130926.51766.CC</pub-id>
                    <pub-id pub-id-type="pmid">15148277</pub-id>
                    <issn>0009-7322</issn>
                </mixed-citation>
            </ref>
            <ref id="b33">
                <label>33. </label> 
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name>
                            <surname>Cardinale</surname>
                            <given-names>D</given-names>
                        </name>, 
                        <name>
                            <surname>Colombo</surname>
                            <given-names>A</given-names>
                        </name>, 
                        <name>
                            <surname>Torrisi</surname>
                            <given-names>R</given-names>
                        </name>, 
                        <name>
                            <surname>Sandri</surname>
                            <given-names>MT</given-names>
                        </name>, 
                        <name>
                            <surname>Civelli</surname>
                            <given-names>M</given-names>
                        </name>, 
                        <name>
                            <surname>Salvatici</surname>
                            <given-names>M</given-names>
                        </name>, 
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>Trastuzumab-induced cardiotoxicity: clinical and prognostic implications of troponin I evaluation</article-title>. 
                    <source>J Clin Oncol</source>. 
                    <year>2010</year>
                    <month>Sep</month>;
                    <volume>28</volume>(
                    <issue>25</issue>):
                    <fpage>3910</fpage>–
                    <lpage>6</lpage>. 
                    <pub-id pub-id-type="doi">10.1200/JCO.2009.27.3615</pub-id>
                    <pub-id pub-id-type="pmid">20679614</pub-id>
                    <issn>0732-183X</issn>
                </mixed-citation>
            </ref>
            <ref id="b34">
                <label>34. </label> 
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name>
                            <surname>Sawaya</surname>
                            <given-names>H</given-names>
                        </name>, 
                        <name>
                            <surname>Sebag</surname>
                            <given-names>IA</given-names>
                        </name>, 
                        <name>
                            <surname>Plana</surname>
                            <given-names>JC</given-names>
                        </name>, 
                        <name>
                            <surname>Januzzi</surname>
                            <given-names>JL</given-names>
                        </name>, 
                        <name>
                            <surname>Ky</surname>
                            <given-names>B</given-names>
                        </name>, 
                        <name>
                            <surname>Tan</surname>
                            <given-names>TC</given-names>
                        </name>, 
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>Assessment of echocardiography and biomarkers for the extended prediction of cardiotoxicity in patients treated with anthracyclines, taxanes, and trastuzumab</article-title>. 
                    <source>Circ Cardiovasc Imaging</source>. 
                    <year>2012</year>
                    <month>Sep</month>;
                    <volume>5</volume>(
                    <issue>5</issue>):
                    <fpage>596</fpage>–
                    <lpage>603</lpage>. 
                    <pub-id pub-id-type="doi">10.1161/CIRCIMAGING.112.973321</pub-id>
                    <pub-id pub-id-type="pmid">22744937</pub-id>
                    <issn>1941-9651</issn>
                </mixed-citation>
            </ref>
            <ref id="b35">
                <label>35. </label> 
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name>
                            <surname>Kalay</surname>
                            <given-names>N</given-names>
                        </name>, 
                        <name>
                            <surname>Basar</surname>
                            <given-names>E</given-names>
                        </name>, 
                        <name>
                            <surname>Ozdogru</surname>
                            <given-names>I</given-names>
                        </name>, 
                        <name>
                            <surname>Er</surname>
                            <given-names>O</given-names>
                        </name>, 
                        <name>
                            <surname>Cetinkaya</surname>
                            <given-names>Y</given-names>
                        </name>, 
                        <name>
                            <surname>Dogan</surname>
                            <given-names>A</given-names>
                        </name>, 
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>Protective effects of carvedilol against anthracycline-induced cardiomyopathy</article-title>. 
                    <source>J Am Coll Cardiol</source>. 
                    <year>2006</year>
                    <month>Dec</month>;
                    <volume>48</volume>(
                    <issue>11</issue>):
                    <fpage>2258</fpage>–
                    <lpage>62</lpage>. 
                    <pub-id pub-id-type="doi">10.1016/j.jacc.2006.07.052</pub-id>
                    <pub-id pub-id-type="pmid">17161256</pub-id>
                    <issn>0735-1097</issn>
                </mixed-citation>
            </ref>
            <ref id="b36">
                <label>36. </label> 
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name>
                            <surname>Kaya</surname>
                            <given-names>MG</given-names>
                        </name>, 
                        <name>
                            <surname>Ozkan</surname>
                            <given-names>M</given-names>
                        </name>, 
                        <name>
                            <surname>Gunebakmaz</surname>
                            <given-names>O</given-names>
                        </name>, 
                        <name>
                            <surname>Akkaya</surname>
                            <given-names>H</given-names>
                        </name>, 
                        <name>
                            <surname>Kaya</surname>
                            <given-names>EG</given-names>
                        </name>, 
                        <name>
                            <surname>Akpek</surname>
                            <given-names>M</given-names>
                        </name>, 
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>Protective effects of nebivolol against anthracycline-induced cardiomyopathy: a randomized control study</article-title>. 
                    <source>Int J Cardiol</source>. 
                    <year>2013</year>
                    <month>Sep</month>;
                    <volume>167</volume>(
                    <issue>5</issue>):
                    <fpage>2306</fpage>–
                    <lpage>10</lpage>. 
                    <pub-id pub-id-type="doi">10.1016/j.ijcard.2012.06.023</pub-id>
                    <pub-id pub-id-type="pmid">22727976</pub-id>
                    <issn>0167-5273</issn>
                </mixed-citation>
            </ref>
            <ref id="b37">
                <label>37. </label> 
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name>
                            <surname>Seicean</surname>
                            <given-names>S</given-names>
                        </name>, 
                        <name>
                            <surname>Seicean</surname>
                            <given-names>A</given-names>
                        </name>, 
                        <name>
                            <surname>Alan</surname>
                            <given-names>N</given-names>
                        </name>, 
                        <name>
                            <surname>Plana</surname>
                            <given-names>JC</given-names>
                        </name>, 
                        <name>
                            <surname>Budd</surname>
                            <given-names>GT</given-names>
                        </name>, 
                        <name>
                            <surname>Marwick</surname>
                            <given-names>TH</given-names>
                        </name>
                    </person-group>. 
                    <article-title>Cardioprotective effect of β-adrenoceptor blockade in patients with breast cancer undergoing chemotherapy: follow-up study of heart failure</article-title>. 
                    <source>Circ Heart Fail</source>. 
                    <year>2013</year>
                    <month>May</month>;
                    <volume>6</volume>(
                    <issue>3</issue>):
                    <fpage>420</fpage>–
                    <lpage>6</lpage>. 
                    <pub-id pub-id-type="doi">10.1161/CIRCHEARTFAILURE.112.000055</pub-id>
                    <pub-id pub-id-type="pmid">23425978</pub-id>
                    <issn>1941-3289</issn>
                </mixed-citation>
            </ref>
            <ref id="b38">
                <label>38. </label> 
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name>
                            <surname>Bosch</surname>
                            <given-names>X</given-names>
                        </name>, 
                        <name>
                            <surname>Rovira</surname>
                            <given-names>M</given-names>
                        </name>, 
                        <name>
                            <surname>Sitges</surname>
                            <given-names>M</given-names>
                        </name>, 
                        <name>
                            <surname>Domènech</surname>
                            <given-names>A</given-names>
                        </name>, 
                        <name>
                            <surname>Ortiz-Pérez</surname>
                            <given-names>JT</given-names>
                        </name>, 
                        <name>
                            <surname>de Caralt</surname>
                            <given-names>TM</given-names>
                        </name>, 
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>Enalapril and carvedilol for preventing chemotherapy-induced left ventricular systolic dysfunction in patients with malignant hemopathies: the OVERCOME trial (preventiOn of left Ventricular dysfunction with Enalapril and caRvedilol in patients submitted to intensive ChemOtherapy for the treatment of Malignant hEmopathies)</article-title>. 
                    <source>J Am Coll Cardiol</source>. 
                    <year>2013</year>
                    <month>Jun</month>;
                    <volume>61</volume>(
                    <issue>23</issue>):
                    <fpage>2355</fpage>–
                    <lpage>62</lpage>. 
                    <pub-id pub-id-type="doi">10.1016/j.jacc.2013.02.072</pub-id>
                    <pub-id pub-id-type="pmid">23583763</pub-id>
                    <issn>0735-1097</issn>
                </mixed-citation>
            </ref>
            <ref id="b39">
                <label>39. </label> 
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name>
                            <surname>Nakamae</surname>
                            <given-names>H</given-names>
                        </name>, 
                        <name>
                            <surname>Tsumura</surname>
                            <given-names>K</given-names>
                        </name>, 
                        <name>
                            <surname>Terada</surname>
                            <given-names>Y</given-names>
                        </name>, 
                        <name>
                            <surname>Nakane</surname>
                            <given-names>T</given-names>
                        </name>, 
                        <name>
                            <surname>Nakamae</surname>
                            <given-names>M</given-names>
                        </name>, 
                        <name>
                            <surname>Ohta</surname>
                            <given-names>K</given-names>
                        </name>, 
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>Notable effects of angiotensin II receptor blocker, valsartan, on acute cardiotoxic changes after standard chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisolone</article-title>. 
                    <source>Cancer</source>. 
                    <year>2005</year>
                    <month>Dec</month>;
                    <volume>104</volume>(
                    <issue>11</issue>):
                    <fpage>2492</fpage>–
                    <lpage>8</lpage>. 
                    <pub-id pub-id-type="doi">10.1002/cncr.21478</pub-id>
                    <pub-id pub-id-type="pmid">16247790</pub-id>
                    <issn>0008-543X</issn>
                </mixed-citation>
            </ref>
            <ref id="b40">
                <label>40. </label> 
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name>
                            <surname>Cadeddu</surname>
                            <given-names>C</given-names>
                        </name>, 
                        <name>
                            <surname>Piras</surname>
                            <given-names>A</given-names>
                        </name>, 
                        <name>
                            <surname>Mantovani</surname>
                            <given-names>G</given-names>
                        </name>, 
                        <name>
                            <surname>Deidda</surname>
                            <given-names>M</given-names>
                        </name>, 
                        <name>
                            <surname>Dessì</surname>
                            <given-names>M</given-names>
                        </name>, 
                        <name>
                            <surname>Madeddu</surname>
                            <given-names>C</given-names>
                        </name>, 
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>Protective effects of the angiotensin II receptor blocker telmisartan on epirubicin-induced inflammation, oxidative stress, and early ventricular impairment</article-title>. 
                    <source>Am Heart J</source>. 
                    <year>2010</year>
                    <month>Sep</month>;
                    <volume>160</volume>(
                    <issue>3</issue>):
                    <fpage>487.e1</fpage>–
                    <lpage>7</lpage>. 
                    <pub-id pub-id-type="doi">10.1016/j.ahj.2010.05.037</pub-id>
                    <pub-id pub-id-type="pmid">20826257</pub-id>
                    <issn>0002-8703</issn>
                </mixed-citation>
            </ref>
            <ref id="b41">
                <label>41. </label> 
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name>
                            <surname>Akpek</surname>
                            <given-names>M</given-names>
                        </name>, 
                        <name>
                            <surname>Ozdogru</surname>
                            <given-names>I</given-names>
                        </name>, 
                        <name>
                            <surname>Sahin</surname>
                            <given-names>O</given-names>
                        </name>, 
                        <name>
                            <surname>Inanc</surname>
                            <given-names>M</given-names>
                        </name>, 
                        <name>
                            <surname>Dogan</surname>
                            <given-names>A</given-names>
                        </name>, 
                        <name>
                            <surname>Yazici</surname>
                            <given-names>C</given-names>
                        </name>, 
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>Protective effects of spironolactone against anthracycline-induced cardiomyopathy</article-title>. 
                    <source>Eur J Heart Fail</source>. 
                    <year>2015</year>
                    <month>Jan</month>;
                    <volume>17</volume>(
                    <issue>1</issue>):
                    <fpage>81</fpage>–
                    <lpage>9</lpage>. 
                    <pub-id pub-id-type="doi">10.1002/ejhf.196</pub-id>
                    <pub-id pub-id-type="pmid">25410653</pub-id>
                    <issn>1388-9842</issn>
                </mixed-citation>
            </ref>
            <ref id="b42">
                <label>42. </label> 
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name>
                            <surname>Cardinale</surname>
                            <given-names>D</given-names>
                        </name>, 
                        <name>
                            <surname>Colombo</surname>
                            <given-names>A</given-names>
                        </name>, 
                        <name>
                            <surname>Sandri</surname>
                            <given-names>MT</given-names>
                        </name>, 
                        <name>
                            <surname>Lamantia</surname>
                            <given-names>G</given-names>
                        </name>, 
                        <name>
                            <surname>Colombo</surname>
                            <given-names>N</given-names>
                        </name>, 
                        <name>
                            <surname>Civelli</surname>
                            <given-names>M</given-names>
                        </name>, 
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition</article-title>. 
                    <source>Circulation</source>. 
                    <year>2006</year>
                    <month>Dec</month>;
                    <volume>114</volume>(
                    <issue>23</issue>):
                    <fpage>2474</fpage>–
                    <lpage>81</lpage>. 
                    <pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.106.635144</pub-id>
                    <pub-id pub-id-type="pmid">17101852</pub-id>
                    <issn>0009-7322</issn>
                </mixed-citation>
            </ref>
            <ref id="b43">
                <label>43. </label> 
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name>
                            <surname>Seicean</surname>
                            <given-names>S</given-names>
                        </name>, 
                        <name>
                            <surname>Seicean</surname>
                            <given-names>A</given-names>
                        </name>, 
                        <name>
                            <surname>Plana</surname>
                            <given-names>JC</given-names>
                        </name>, 
                        <name>
                            <surname>Budd</surname>
                            <given-names>GT</given-names>
                        </name>, 
                        <name>
                            <surname>Marwick</surname>
                            <given-names>TH</given-names>
                        </name>
                    </person-group>. 
                    <article-title>Effect of statin therapy on the risk for incident heart failure in patients with breast cancer receiving anthracycline chemotherapy: an observational clinical cohort study</article-title>. 
                    <source>J Am Coll Cardiol</source>. 
                    <year>2012</year>
                    <month>Dec</month>;
                    <volume>60</volume>(
                    <issue>23</issue>):
                    <fpage>2384</fpage>–
                    <lpage>90</lpage>. 
                    <pub-id pub-id-type="doi">10.1016/j.jacc.2012.07.067</pub-id>
                    <pub-id pub-id-type="pmid">23141499</pub-id>
                    <issn>0735-1097</issn>
                </mixed-citation>
            </ref>
            <ref id="b44">
                <label>44. </label> 
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name>
                            <surname>Ponikowski</surname>
                            <given-names>P</given-names>
                        </name>, 
                        <name>
                            <surname>Voors</surname>
                            <given-names>AA</given-names>
                        </name>, 
                        <name>
                            <surname>Anker</surname>
                            <given-names>SD</given-names>
                        </name>, 
                        <name>
                            <surname>Bueno</surname>
                            <given-names>H</given-names>
                        </name>, 
                        <name>
                            <surname>Cleland</surname>
                            <given-names>JG</given-names>
                        </name>, 
                        <name>
                            <surname>Coats</surname>
                            <given-names>AJ</given-names>
                        </name>, 
                        <etal>et al</etal>; 
                        <collab>ESC Scientific Document Group</collab>
                    </person-group>. 
                    <article-title>2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC</article-title>. 
                    <source>Eur Heart J</source>. 
                    <year>2016</year>
                    <month>Jul</month>;
                    <volume>37</volume>(
                    <issue>27</issue>):
                    <fpage>2129</fpage>–
                    <lpage>200</lpage>. 
                    <pub-id pub-id-type="doi">10.1093/eurheartj/ehw128</pub-id>
                    <pub-id pub-id-type="pmid">27206819</pub-id>
                    <issn>0195-668X</issn>
                </mixed-citation>
            </ref>
            <ref id="b45">
                <label>45. </label> 
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name>
                            <surname>Fadol</surname>
                            <given-names>AP</given-names>
                        </name>
                    </person-group>. 
                    <article-title>Management of Chemotherapy-Induced Left Ventricular Dysfunction and Heart Failure in Patients With Cancer While Undergoing Cancer Treatment: the MD Anderson Practice</article-title>. 
                    <source>Front Cardiovasc Med</source>. 
                    <year>2018</year>
                    <month>Mar</month>;
                    <volume>5</volume>:
                    <fpage>24</fpage>. 
                    <pub-id pub-id-type="doi">10.3389/fcvm.2018.00024</pub-id>
                    <pub-id pub-id-type="pmid">29644219</pub-id>
                    <issn>2297-055X</issn>
                </mixed-citation>
            </ref>
        </ref-list>
    </back>
</article>